Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M D Percival

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Biochemistry|September 21, 1993
Characterization of the non-heme iron center of human 5-lipoxygenase by electron paramagnetic resonance, fluorescence, and ultraviolet-visible spectroscopy: redox cycling between ferrous and ferric statesN D Chasteen, J K Grady, K I Skorey, et al.
Archives of Biochemistry and Biophysics|November 15, 1994
Purification and characterization of recombinant human cyclooxygenase-2M D Percival, M Ouellet, C J Vincent, et al.
Osteoarthritis and Cartilage|April 12, 2008
The type II collagen fragments Helix-II and CTX-II reveal different enzymatic pathways of human cartilage collagen degradationN Charni-Ben Tabassi, S Desmarais, A-C Bay-Jensen, et al.
Molecular Pharmacology|November 14, 1997
The interaction of arginine 106 of human prostaglandin G/H synthase-2 with inhibitors is not a universal component of inhibition mediated by nonsteroidal anti-inflammatory drugsG M Greig, D A Francis, J P Falgueyret, et al.
Journal of Medicinal Chemistry|January 5, 2001
Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and LJ P Falgueyret, R M Oballa, O Okamoto, et al.
British Journal of Pharmacology|May 1, 1997
Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitorD Riendeau, M D Percival, S Boyce, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 20, 1999
Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profilesC C Chan, S Boyce, C Brideau, et al.
Bioorganic & Medicinal Chemistry Letters|July 16, 1999
The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitorP Prasit, Z Wang, C Brideau, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 13, 2001
Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2D Riendeau, M D Percival, C Brideau, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Biochemistry|September 21, 1993
Characterization of the non-heme iron center of human 5-lipoxygenase by electron paramagnetic resonance, fluorescence, and ultraviolet-visible spectroscopy: redox cycling between ferrous and ferric statesN D Chasteen, J K Grady, K I Skorey, et al.
Archives of Biochemistry and Biophysics|November 15, 1994
Purification and characterization of recombinant human cyclooxygenase-2M D Percival, M Ouellet, C J Vincent, et al.
Osteoarthritis and Cartilage|April 12, 2008
The type II collagen fragments Helix-II and CTX-II reveal different enzymatic pathways of human cartilage collagen degradationN Charni-Ben Tabassi, S Desmarais, A-C Bay-Jensen, et al.
Molecular Pharmacology|November 14, 1997
The interaction of arginine 106 of human prostaglandin G/H synthase-2 with inhibitors is not a universal component of inhibition mediated by nonsteroidal anti-inflammatory drugsG M Greig, D A Francis, J P Falgueyret, et al.
Journal of Medicinal Chemistry|January 5, 2001
Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and LJ P Falgueyret, R M Oballa, O Okamoto, et al.
British Journal of Pharmacology|May 1, 1997
Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitorD Riendeau, M D Percival, S Boyce, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 20, 1999
Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profilesC C Chan, S Boyce, C Brideau, et al.
Bioorganic & Medicinal Chemistry Letters|July 16, 1999
The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitorP Prasit, Z Wang, C Brideau, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 13, 2001
Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2D Riendeau, M D Percival, C Brideau, et al.
Pageof 3